COVID-19 in patients with hidradenitis suppurativa.
作者信息
Lima X T, Cueva M A, Alora M B
机构信息
Massachusetts General Hospital, Clinical Unit for Research Trials in Skin, Boston, MA, USA.
Dermatology Division, Internal Medicine Department, Federal University of Ceará, Fortaleza, Ceará, Brazil.
出版信息
Br J Dermatol. 2021 Jan;184(1):182-184. doi: 10.1111/bjd.19492. Epub 2020 Sep 24.
Abstract
摘要
相似文献
1
COVID-19 in patients with hidradenitis suppurativa.化脓性汗腺炎患者中的新型冠状病毒肺炎
Br J Dermatol. 2021 Jan;184(1):182-184. doi: 10.1111/bjd.19492. Epub 2020 Sep 24.
2
Biologic drugs during COVID-19 outbreak.2019冠状病毒病疫情期间的生物药物
Int J Dermatol. 2020 Oct;59(10):1293. doi: 10.1111/ijd.15088. Epub 2020 Aug 6.
3
Association between sex and SARS-CoV-2 infection and hospitalisation as a result of COVID-19.性别与SARS-CoV-2感染以及因COVID-19导致住院之间的关联。
Lancet Respir Med. 2021 Aug;9(8):e75-e76. doi: 10.1016/S2213-2600(21)00239-3. Epub 2021 Jun 18.
4
Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy.COVID-19 大流行期间化脓性汗腺炎患者的管理：免疫调节治疗的风险和获益。
Dermatol Ther. 2020 Nov;33(6):e14256. doi: 10.1111/dth.14256. Epub 2020 Sep 14.
5
No impact of immunomodulatory treatments on SARS-CoV-2 (COVID-19) vaccine outcomes: A cross-sectional analysis of biologic and small molecule inhibitors used for psoriasis and hidradenitis suppurativa patients from the Epic Cosmos database.免疫调节治疗对SARS-CoV-2（新冠病毒病）疫苗效果无影响：对Epic Cosmos数据库中用于银屑病和化脓性汗腺炎患者的生物制剂和小分子抑制剂的横断面分析
J Am Acad Dermatol. 2024 Jul;91(1):100-102. doi: 10.1016/j.jaad.2024.03.004. Epub 2024 Mar 13.
6
Global Hidradenitis Suppurativa COVID-19 Registry: a registry to inform data-driven management practices.全球化脓性汗腺炎新型冠状病毒肺炎登记处：一个为基于数据的管理实践提供信息的登记处。
Br J Dermatol. 2020 Oct;183(4):780-781. doi: 10.1111/bjd.19345. Epub 2020 Aug 2.
7
Association between viral control and severity of hidradenitis suppurativa in a cohort of patients with comorbid human immunodeficiency virus and hidradenitis suppurativa.合并人类免疫缺陷病毒和化脓性汗腺炎患者队列中病毒控制与化脓性汗腺炎严重程度之间的关联
Arch Dermatol Res. 2024 Jun 21;316(7):423. doi: 10.1007/s00403-024-03171-1.
8
Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis.化脓性汗腺炎是一种系统性疾病，具有较大的合并症负担：基于图表验证的病例对照分析。
J Am Acad Dermatol. 2014 Dec;71(6):1144-50. doi: 10.1016/j.jaad.2014.09.012. Epub 2014 Oct 14.
9
Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab.监测接受托珠单抗治疗的2019冠状病毒病患者的中性粒细胞与淋巴细胞比值。
Ann Allergy Asthma Immunol. 2021 Mar;126(3):306-308. doi: 10.1016/j.anai.2020.12.014. Epub 2020 Dec 30.
10
Coronavirus infection in a high-risk obstetrical population of the South Bronx, New York.纽约市布朗克斯区南部高危产科人群中的冠状病毒感染情况。
Am J Obstet Gynecol MFM. 2020 Nov;2(4):100203. doi: 10.1016/j.ajogmf.2020.100203. Epub 2020 Aug 18.
引用本文的文献
1
COVID-19 Infection in Hidradenitis Suppurativa Patients: A Retrospective Study.化脓性汗腺炎患者的新冠病毒感染：一项回顾性研究
Skin Appendage Disord. 2023 Jun;9(3):203-206. doi: 10.1159/000529462. Epub 2023 Mar 9.
2
Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts.化脓性汗腺炎患者新冠疫苗接种指南：专家修改后的德尔菲共识
Skin Appendage Disord. 2022 Jul;8(4):287-290. doi: 10.1159/000521268. Epub 2022 Jan 10.
3
Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.新冠疫情期间接受生物制剂治疗的银屑病和化脓性汗腺炎患者的皮肤表现
J Clin Med. 2021 Dec 13;10(24):5841. doi: 10.3390/jcm10245841.
4
Low incidence of COVID-19 in hidradenitis suppurativa: How to interpret it?化脓性汗腺炎中新冠病毒感染的低发病率：该如何解读？
Exp Dermatol. 2022 Mar;31(3):435-436. doi: 10.1111/exd.14475. Epub 2021 Nov 3.
5
Coronavirus disease 2019 complications in patients with hidradenitis suppurativa: A multicenter analysis.化脓性汗腺炎患者的2019冠状病毒病并发症：一项多中心分析。
J Dermatol. 2021 Oct;48(10):1619-1621. doi: 10.1111/1346-8138.16073. Epub 2021 Aug 17.
6
Anti-COVID-19 measurements for hidradenitis suppurativa patients.防治化脓性汗腺炎患者感染 COVID-19 的措施。
Exp Dermatol. 2021 Jun;30 Suppl 1(Suppl 1):18-22. doi: 10.1111/exd.14339.
本文引用的文献
1
Experience in patients with hidradenitis suppurativa and COVID-19 symptoms.化脓性汗腺炎合并新冠病毒疾病症状患者的经验
J Am Acad Dermatol. 2020 Oct;83(4):e309-e311. doi: 10.1016/j.jaad.2020.06.986. Epub 2020 Jun 27.
2
Global Hidradenitis Suppurativa COVID-19 Registry: a registry to inform data-driven management practices.全球化脓性汗腺炎新型冠状病毒肺炎登记处：一个为基于数据的管理实践提供信息的登记处。
Br J Dermatol. 2020 Oct;183(4):780-781. doi: 10.1111/bjd.19345. Epub 2020 Aug 2.
3
Moderate-to-severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak.2019年冠状病毒病疫情期间接受全身治疗的中重度化脓性汗腺炎
Dermatol Ther. 2020 Jul;33(4):e13680. doi: 10.1111/dth.13680. Epub 2020 Jun 18.
4
Exploring the risk of severe COVID-19 infection in patients with hidradenitis suppurativa.探究化脓性汗腺炎患者发生重症新型冠状病毒肺炎感染的风险。
J Am Acad Dermatol. 2020 Aug;83(2):e153-e154. doi: 10.1016/j.jaad.2020.05.012. Epub 2020 May 8.
5
COVID-19 and racial disparities.新型冠状病毒肺炎与种族差异。
J Am Acad Dermatol. 2020 Jul;83(1):e35. doi: 10.1016/j.jaad.2020.04.046. Epub 2020 Apr 17.
6
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
7
Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis.化脓性汗腺炎：流行病学、临床表现和发病机制。
J Am Acad Dermatol. 2020 May;82(5):1045-1058. doi: 10.1016/j.jaad.2019.08.090. Epub 2019 Oct 9.
Zotero 插件